⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945427 | 0.90 | — | — | |
| SCHEMBL5393971 | 0.89 | — | — | |
| SCHEMBL4039074 | 0.88 | — | — | |
| SCHEMBL4042053 | 0.88 | — | — | |
| SCHEMBL5663043 | 0.88 | — | — | |
| SCHEMBL4040424 | 0.88 | — | — | |
| SCHEMBL4038979 | 0.86 | — | — | |
| SCHEMBL5667833 | 0.86 | — | — | |
| SCHEMBL5667838 | 0.86 | — | — | |
| SCHEMBL5663356 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664052-B1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | claimed |
| US-7371757-B2 | Fused heterocycles as inhibitors of glutamate racemase(MURI) | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | claimed |
| JP-2007502307-A | — | — | 2007-02-08 | — | — | JP | claimed |
| US-20060252781-A1 | Fused heterocycles as inhibitors of glutamate racemase(muri) | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | US | claimed |
| EP-1664052-A1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | claimed |
| WO-2005016929-A1 | FUSED HETEROCYLCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | claimed |
| EP-1664052-B1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| US-7371757-B2 | Fused heterocycles as inhibitors of glutamate racemase(MURI) | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7371757-B2 | Fused heterocycles as inhibitors of glutamate racemase(MURI) | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7371757-B2 | Fused heterocycles as inhibitors of glutamate racemase(MURI) | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-20060252781-A1 | Fused heterocycles as inhibitors of glutamate racemase(muri) | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | US | disclosed |
| EP-1664052-A1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005016929-A1 | FUSED HETEROCYLCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | disclosed |